Analytical Data
-
Gene name
SMG6
- Application
-
Alternative Names
C17orf31; EST1A; KIAA0732
-
Species
Human
-
Source
E. coli
-
Tag
Strep;His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q86US8-1
-
Expression Region
E580-E1166
-
Protein Length
Partial
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SMG6, a key component of the nonsense-mediated mRNA decay (NMD) pathway, plays a critical role in maintaining mRNA quality control by recognizing and degrading mRNAs containing premature stop codons. Research into the recombinant expression and purification of SMG6 has gained increased attention due to its vital functions in post-transcriptional regulation and its implications in various diseases, including cancer and genetic disorders. The SMG6 protein possesses both endonuclease and RNA-binding domains, which contribute to its role in the selective degradation of faulty mRNAs. By studying the structure and function of recombinant SMG6, researchers aim to uncover the mechanisms behind its interaction with other proteins involved in the NMD pathway and to elucidate its potential as a therapeutic target. Additionally, understanding how SMG6 recognizes aberrant mRNAs can provide insights into the broader regulatory networks governing gene expression. The development of stable recombinant SMG6 can pave the way for high-throughput screenings and functional assays, further enhancing our understanding of RNA metabolism and its relevance in cellular physiology and disease pathology.
